Document:

Sales Agency Agreement by and between Alphatec Spine Inc. and Fusion Medical Inc

 Exhibit 10.26 
 CONFIDENTIAL TREATMENT REQUESTED 
 ALPHATEC SPINE, INC. SALES AGENCY AGREEMENT 
 This Sales Agency Agreement (the “Agreement”) is between Alphatec Spine, Inc., a California corporation (the “Company”) and Fusion
Medical, Inc. (Employer Identification Number                     ) (hereinafter referred to as “Sales Agent”) is made as of
January 4, 2007 (the “Effective Date”). 
 WHEREAS Sales Agent has established and maintained a business office staffed with
professional sales personnel in the Territory (as hereinafter defined); and 
 WHEREAS the Company wishes to retain Sales Agent to sell its
Products (as hereinafter defined) and Sales Agent wishes to act as the Company’s exclusive Sales Agent within the Territory. 
 NOW
THEREFORE, in consideration of the mutual covenants and provisions herein contained, and other good and valuable consideration, the receipt and sufficiency of which is acknowledged by the parties hereto the parties agree as follows: 
  

	1.	APPOINTMENT OF SALES AGENT 

 Subject to the
provisions of the Agreement, the Company hereby appoints Sales Agent and Sales Agent hereby accepts appointment as the Sales Agent for the products described in Exhibit A (hereinafter the “Products”) with responsibility for the
geographical areas listed on Exhibit B (hereinafter the “Territory”). Sales Agent shall have the right to solicit orders for Products only from persons and entities having their places of business within the Territory that agree to
use the Products so ordered within the Territory. 
  

	2.	SALES AGENTS’ OBLIGATIONS 

 In addition to any
and all covenants, duties and obligations of Sales Agent set forth elsewhere in this Agreement, Sales Agent agrees: 
 2.1. To use its best
efforts to promote the sale of the Products throughout the Territory; 
 2.2. To use its best efforts to meet the sales quotas set forth on
Exhibit D; 
 2.3. To bear all costs and liabilities relating to the conduct of its business, including but not limited to the cost
and expense of providing and maintaining its place of business, the wages of its employees, the payment of commissions or other compensation to its agents or independent contractors, and its expenses incurred for or in connection with its
performance under or breach of this Agreement; 
 2.4. To refrain from making any representations or warranties in respect of the Products,
except: (i) those representations and warranties authorized in writing by the Company, in the form of brochures, memorandums, press releases, advertisements, specification sheets, or correspondences, and (ii) verbal technical assistance
that Sales Agent received from the Company which was subsequently confirmed in writing by Sales Agent; 
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 2.5. To promote the Products in strict adherence to (i) regulatory and professional
requirements, and all applicable laws, rules, guidelines and regulations including, but not limited to, the Federal Food, Drug and Cosmetic Act of 1938, as amended, and the regulations promulgated thereunder (the “Act”); and
(ii) those portions of the Company’s Code of Conduct that address interactions with healthcare professionals (available at http://atec.client.shareholder.com/documentdisplay.cfm?DocumentID=900); 
 2.6. To render reasonable assistance to the Company, at the Company’s request, in the defense of any and all Liabilities (as defined below);

 2.7. To refrain from disparaging the Company and its subsidiaries or its Products, or from otherwise injuring the reputation and good
standing of the Company and its subsidiaries; 
 2.8. To not, directly or indirectly, solicit any sale of the Products or establish any
branch or distribution depot for the sale of the Products outside the Territory without the prior written approval of the Company; 
 2.9.
Take full responsibility for the actions of any Sales Agent Indemnitee (as defined below); 
 2.10. To assist the Company, on request, in
ascertaining the credit standing of and in collecting receivables from any customer; and 
 2.11. To attend, at its own expense, all sales
meetings, training sessions, seminars, trade shows and the like for which the Company reasonably requests attendance by Sales Agent. 
 2.12.
To immediately notify the Company prior to any person who prescribes the Company’s Products (‘the “Prescriber”) acquiring an equity interest in the Sales Agent, and upon such instance to provide in writing a listing, by
percentage of equity interest owned, of all Prescribers that have an equity interest in the Sales Agent at the time of each disclosure. A breach of this Section 2.12 shall constitute a material breach of this Agreement. 
 2.13. To deliver all Products using documented procedures for handling, storage, packing, preservation, and delivery of such Products. 
 2.14. To promptly notify the Company in writing of the following: (i) any serious regulatory action relating to the Products; (ii) any material
complaints regarding the Products or the related instrumentation; or (iii) any adverse incidents that may be subject to FDA’s (as hereinafter defined) Medical Device Reporting regulation. 
 2.15. To comply with recalls or general corrective actions initiated by the Company. 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

	3.	ALPHATEC’S DUTIES AND OBLIGATIONS 

 In order to
assist Sales Agent in fostering the promotion and sale of the Company’s Products, the Company agrees: 
 3.1. To reasonably assist Sales
Agent with advertising material, sales promotion aids, displays, catalogues, literature and convention assistance; 
 3.2. To provide Sales
Agent with new Product information and reasonably assist Sales Agent in promotional activities; 
 3.3. To provide Sales Agent with
reasonable technical assistance, through sales seminars, meetings and training programs; and 
 3.4. To use commercially reasonable efforts
to make Products available to the Sales Agent to be used by customers. 
  

	4.	QUOTATIONS, ORDERS AND PAYMENT BY CUSTOMERS 

 4.1.
Sales Agent will make quotations in respect to the sales of the Products only in accordance with the Company’s then current policies and procedures and on prices established by the Company and the Company’s terms and conditions of sale,
including the terms of payment specified by the Company. The Sales Agent will assist the Company in obtaining the appropriate documentation needed for customers (credit reports, sales tax exemptions, etc.). 
 4.2. Sales orders generated by Sales Agent will be submitted directly to the Company by the customer. If Sales Agent receives any order for Products, it
will promptly forward it to the Company. The Company will establish and promulgate the criteria for sales orders to be generated by Sales Agent and Sales Agent will use its best efforts to secure sales orders that meet the Company’s criteria.
The Company will have the right at any time to reject any order in whole or in part. If the Company reasonably rejects any sales order generated by Sales Agent, then Sales Agent shall be notified and given the opportunity to inform its customer or
potential customer of said rejection in an attempt to preserve Sales Agent’s business goodwill. On request of the Company, Sales Agent will not supply Product to customers placed on credit hold until released by the Company. 
 4.3. The Company will bill the customer for the purchased Products. Sales Agent will not bill customers for the Product unless expressly requested to do
so by the Company in writing. Payments against purchase orders are to be made directly to the Company, without intervention by Sales Agent unless expressly requested in writing by the Company in each instance. If Sales Agent receives any payment
from a customer, then Sales Agent will immediately forward the entire amount of such payment to the Company. 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 4.4. The Company will have the right, in its sole discretion, to issue credits, make discounts and
allowances, and/or accept returns of the Products. Sales Agent in an effort to be competitive with the orthopedic market or to develop new customers will have the right to request the Company to issue credits, make discounts and allowances and/or
accept returns of the Products. The Company shall use its sole discretion in determining whether to grant Sales Agent’s request. 
  

	5.	COMMISSIONS 

 5.1. Except as set forth in this
Agreement, during the term of this Agreement the Company will pay to Sales Agent a commission at the rate specified in Exhibit C on the Company’s Net Sales (as defined below) of Products in the Territory that were generated by the Sales
Agent in accordance with this Agreement. For purposes of this Agreement, the terms “Net Sales” shall mean, for any period, the gross amount properly set forth on a purchase order received by the Company from the customer in connection with
such customer’s purchase of Product, less deductions for: (i) normal and customary quantity and/or cash discounts, including, without limitation, those granted on account of price adjustments, rebates actually allowed and taken,
administrative or other fees or reimbursements or similar payments to buying groups, pharmacy benefit management organizations, health care insurance carriers or other institutions, fees paid to other distributors and chargebacks; (ii) freight,
postage, shipping, and related insurance expenses; (iii) customs or excise duties or other duties directly imposed and related to the sales making up the gross purchase order amount; (iv) any rebates or similar payments made with respect
to sales paid for by any governmental or regulatory authority such as, by way of illustration and not in limitation of the parties’ rights hereunder, Federal or state Medicaid, Medicare or similar state program or equivalent foreign
governmental program; (v) sales and other taxes and duties directly related to the sale of Products, to the extent that such items are included in the gross purchase order price (but not including taxes assessed against the income derived from
such sale); and (vi) any such amounts included in the purchase order that are not collected by the Company which are over 90 days past due and are recorded on the books of the Company as bad debt in accordance with generally accepted accounting
principles. For purposes of determining commissions, the Product shall be deemed to be sold when a properly executed purchase order is received by the Company from the customer in connection with such sale, and a “sale” shall not include
transfers or dispositions for charitable, promotional, pre-clinical, clinical, regulatory, or governmental purposes. 
 5.2. If new product
lines are added to the Product list the commission rate related to such new Product shall be set forth on Exhibit C attached hereto. The parties agree and acknowledge that the Company shall have sole decision-making authority in connection
with establishing commission rates for product lines added to the Product list after the Effective Date. 
 5.3. The Sales Agent agrees to
promptly submit an invoice to the Company in connection with each sale and that all such invoices for payment shall include a listing of all lot numbers of the Products that were sold in connection with such invoice. 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 5.4. Commissions will be released to the Sales Agent on the 30th day after the close of the month in
which the applicable sales are made, or in the event that such day is not a business day, on the next business day. Any commissions paid on outstanding accounts receivable at the close of the month that exceed the payment terms of net 90 days will
be deducted from the Sales Agent’s outstanding commission or invoiced to Sales Agent pursuant to Section 5.6. Upon collection of past due accounts commissions will be re-posted to the Sales Agent. 
 5.5. The Company will keep and maintain accurate, complete and current books and records relating to commissions earned by Sales Agent. Upon payment of
commission to Sales Agent by the Company, the Company shall provide Sales Agent with a detailed breakdown of the customer sales used to calculate the commission as well as any credit, discount, allowance or set-off taken by the Company or applied
against Sales Agent commission. Any discrepancies must be reported to the Company within 30 days of the receipt of the detailed statement. Once per calendar year, upon written request from Sales Agent, the Company will permit an independent
certified public accountant designated by and at the expense of Sales Agent to audit the Company’s books and records pertaining to commissions earned by Sales Agent, such audit to be conducted on the Company’s premises during normal
business hours. 
 5.6. In the event that the Company has previously paid Sales Agent commissions on sales to a customer whose account is
subsequently entitled to a credit, for returns or otherwise, and sufficient commission is not available to deduct the credit within the period, the Company will submit an invoice and a written explanation containing the reasons why the Company is
entitled to reimbursement by Sales Agent of any portion or all of the commission previously paid to Sales Agent. Sales Agent agrees to pay all properly invoiced amounts within 30 days of receipt of said invoice. 
 5.7. The Company will have no liability whatsoever to Sales Agent for commission payments for the Company’s rejection of all or part of any order.

  

	6.	SALES OBJECTIVE 

 6.1. The Company will establish
sales objectives for Products to be sold by the Sales Agent within the Territory as measured in dollar volume. Such sales quotas shall be set forth on Exhibit D attached hereto. To the extent that a sales quota is not included in Exhibit
D, the Company shall have the right to modify such Exhibit D to include a reasonable sales quota. 
 6.2. If new product lines are added
to the Product list an additional quota will be established for such new Product and such quota shall be set forth on Exhibit D. 
  

	7.	SAMPLES, PROMOTIONAL MATERIALS AND INSTRUMENTS 

 7.1. From time to time the Company may deliver to Sales Agent such items as samples, models, literature, promotional materials (the “Samples”) for use in promoting and selling the Products. Except for items actually purchased by
Sales Agent or delivered by Sales 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
Agent as unrestricted no-charge samples according to the Company’s specific instructions, the Company will retain all right, title and interest in and
to the Samples and Sales Agent will hold them in a fiduciary capacity and only use such Samples as permitted in this Agreement. Upon the termination or expiration of this Agreement or upon the request of the Company, the Sales Agent shall return all
Samples to the Company. 
 7.2. Sales Agent will prepare and maintain accurate, complete and current books and records pertaining to the
Samples that are owned by the Company, including but not limited to type and quantity of each item and disposition thereof. 
 7.3. The
Company shall establish for Sales Agent a Products inventory account. Except for the Products actually purchased by Sales Agent, the Company will retain all right, title and interest in and to such Products and related instrumentation (the
“Consigned Inventory”). Sales Agent will hold said Products and related instrumentation in a fiduciary capacity under a separate account titled “Consigned Inventory”. 
 7.4. The Company may request a physical inventory of its property held as Consigned Inventory by Sales Agent. The Company, at its expense, may review
books and records of Sales Agent as they relate to Consigned Inventory as well as to physically audit the Consigned Inventory, and Sales Agent agrees to cooperate with such review. 
 7.5. The level of Consigned Inventory for Sales Agent shall be established upon mutual agreement between the Company and Sales Agent. 
 7.6. The level of total Consigned Inventory for Sales Agent will be reviewed each quarter. Except to the extent that such Consigned Inventory has been
consigned to a hospital in accordance with Section 7.7, if any Consigned Inventory is returned damaged, then the Company, to the extent possible, will repair or refurbish the Consigned Inventory and invoice Sales Agent for the cost of said
repairs and handling. Except to the extent that such Consigned Inventory has been consigned to a hospital in accordance with Section 7.7, if any Consigned Inventory is lost, missing, stolen, or cannot be repaired, then the Company shall invoice
Sales Agent for [***]% of the list price of such Consigned Inventory. 
 7.7. Sales Agent will prepare and maintain complete and accurate
books and records pertaining to all Consigned Inventory, including but not limited to the type and quantity of each Product as well as the disposition thereof. Sales Agent will supply the Company with a copy of each agreement, the form of which is
attached hereto as Exhibit E, where Consignment Inventory is stocked by a hospital, on Sales Agent’s premises or other mutually acceptable place during normal business hours following ten days’ prior written notice to Sales Agent.

 7.8. Upon the termination or expiration of this Agreement, or upon the request of the Company, the Sales Agent shall immediately, and at
its own expense, return all Consignment Inventory in its possession or control to the Company. 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

	8.	SALES ACTIVITY BY ALPHATEC 

 8.1. The Company
reserves the right, at any time and from time to time, throughout the term of this Agreement, to use its employees to engage in selling, promoting and/or other related activities concerning the Products in the Territory in the event that the Company
reasonably determines that the Sales Agent is not actively pursuing sales activities in the Territory (notwithstanding the fact that Sales Agent may be achieving its sales quotas). Any such sales by the Company’s employees will not be credited
to Sales Agent’s account for purposes of determining the achievement of sales quotas and calculating commissions. Prior to the commencement of any sales activity related to Products in the Territory by the Company’s employees, the Company
shall notify the Sales Agent of its intention to begin such activities. 
 8.2. The Company reserves the right to sell the Products within
the Territory to any person or entity offering to purchase and resell the Products as private label products so long as such person or entity is not at such time a company or person to whom Sales Agent is actually selling the Products. In the event
that private labeling occurs, if any, within the Territory, the Company may, but is not obligated to, modify Sales Agent’s sales quotas to reflect the competitive impact of private labeling. 
 8.3. The Company also reserves the right to sell the Products within the Territory to any Company-designated national, regional, or government person or
entity, and Sales Agent shall service such account within the Territory in return for the applicable commission set forth in Exhibit C. If Sales Agent declines to service any such account, the Company shall service such account itself and at
its own expense, and Sales Agent shall receive no commission with respect to such account and such sales shall not be credited to the Sales Agent for purposes of determining the achievement of sales quotas. 
 8.4. The parties agree and acknowledge that under certain circumstances, the Company may find it necessary to establish certain customers as house
accounts. Justification for designation of a customer as a house account includes, without limitation, any customer having sales, service, marketing or technical service requirements beyond the facilities and abilities of Sales Agent, or any
customer that indicated to the Company an unwillingness to use the services of the Sales Agent. The Company reserves the right to deal directly with such house accounts for sale of the Products, which may include delivery of the Products within the
Territory, and in such instances no commission shall be paid on sales to house accounts and such sales shall not be credited to the Sales Agent for purposes of determining the achievement of sales quotas. The Company shall pay Sales Agent such
commissions as are agreed upon between the Company and the Sales Agent for the services, if any, rendered by Sales Agent at the request of the Company in connection with sales of the Products to such house accounts that are delivered within the
Territory. 
 8.5. The Company reserves the right to negotiate and establish clinical investigators and/or clinical centers to conduct
clinical evaluations of the Products within the Territory. The Company may find it necessary to implement certain remuneration programs to the clinical 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
investigators/clinical centers as compensation for sales of the Products, which may include delivery of the Products within the Territory. The Company shall
pay such commissions to Sales Agent as are agreed upon between the Company and the Sales Agent for services, if any, rendered by Sales Agent at the request of the Company in connection with sales of Products obtained from these clinical
investigators/clinical centers located within the Territory. If no services are rendered by Sales Agent, then no commission shall be payable to Sales Agent and such sales shall not be credited to the Sales Agent for purposes of determining the
achievement of sales quotas. 
 8.6. The Company reserves the right to work with any surgeon or medical center in the design and development
of new products. The Company may find it necessary to provide special remuneration programs to the surgeon inventors/medical centers as compensation for their assistance and expertise in new product development. The Company reserves the right to
deal directly with such surgeon inventors/medical centers for the sale of Products. The Company shall pay to Sales Agent such commissions as are agreed upon between the Company and the Sales Agent for services, if any, rendered by Sales Agent at the
request of the Company in connection with sales of the Products to such surgeons/inventors/medical centers located within the Territory. If no services are rendered by Sales Agent, then no commission shall be payable to Sales Agent and such sales
shall not be credited to the Sales Agent for purposes of determining the achievement of sales quotas. 
  

	9.	RELATIONSHIP OF PARTIES 

 Sales Agent is an
independent contractor having only such authority to act for the Company as is expressly set forth in this Agreement. Sales Agent is not authorized to enter into any commitment or contract of any kind on behalf of the Company. The Company will not
incur any liability whatsoever to any third party by reason of Sales Agent having exceeded its authority under the appointment granted by the Company herein or by reason of any misrepresentation by Sales Agent of its relationship to the Company or
of the Company’s products, warranties, policies, practices or procedures. Nothing contained in this Agreement is intended to be construed as creating or implying a relationship of principal and agent or employer and employee between the Company
and Sales Agent or between the Company and Sales Agent’s employees or agents, or a joint venture or partnership between the Company and Sales Agent. 
  

	10.	COMPLIANCE WITH LAWS AND REGULATIONS; NO CONFLICTS; DUE AUTHORIZATION 

 10.1 Nothing in this Agreement shall require either party to take any action which would violate any governmental regulation or law to which either of them is subject. Sales Agent shall, at its sole cost and expense,
obtain in the Territory such governmental approvals, licenses or permits as may be necessary to effectuate the purposes of this Agreement, and shall comply with all federal, state and local laws, regulations and rulings of governmental bodies having
jurisdiction over Sales Agent’s business, in respect of the sale of the Products, including, without limitation, the Act. 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 10.2 The Sales Agent hereby represents and warrants to the Company that neither the execution of this
Agreement by the Sales Agent nor the performance of this Agreement by the Sales Agent or any Sales Agent Indemnitee (as defined below) will (i) violate any order, judgment or injunction applicable to the Sales Agent or any Sales Agent
Indemnitee, or (ii) conflict with or breach any agreement to which the Sales Agent or any Sales Agent Indemnitee are a party or by which the Sales Agent or any Sales Agent Indemnitee are bound. 
 10.3 Each party represents and warrants to the other party: (i) that such party is duly organized and validly existing under the laws of the state
of its organization and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof; (ii) such party is duly authorized to execute and deliver this Agreement and to perform its obligations
hereunder; (iii) the person executing this Agreement on such party’s behalf has been duly authorized to do so by all requisite corporate action; and (iv) this Agreement is a legal and valid obligation binding upon the parties and
enforceable in accordance with its terms. 
  

	11.	REPORTS 

 Sales Agent may be requested from time to
time to submit to the Company written reports of Sales Agent’s activities performed under this Agreement. Such reports will include a listing, by name and location, of customers contacted by Sales Agent, major opportunities being pursued,
inquiries and/or problems reported by customers, physicians and/or users of the Products, Sales Agent’s recommendations respecting actions to be taken by the Company to secure sales, and any other pertinent matters requested by the Company to
be included in such reports, for the relevant period to which the report applies. 
  

	12.	INDEMNIFICATION 

 12.1. Sales Agent shall indemnify,
defend and hold harmless the Company, and its officers, directors, employees, affiliates and agents (the “Company Indemnitees”) from all claims, damages, losses, costs and expenses (including reasonable attorneys’ fees) (the
“Liabilities”) which any Company Indemnitee may incur to the extent that such Liabilities arise out of or result from: (i) any representation or warranty given by Sales Agent with respect to the Products (other than the labeling of
the Products as approved by the United States Food and Drug Administration (the “FDA”), (ii) the manufacture, use or sale of any product which is not supplied by Company and which is sold or combined with a Product, (iii) the
breach of any representation, warranty, or covenant of the Sales Agent contained in this Agreement; or (iv) the negligence, recklessness, gross negligence, or willful misconduct of Sales Agent or any Sales Agent Indemnitee. 
 12.2. Company shall indemnify and hold harmless Sales Agent and its officers, directors, employees, affiliates and agents (the “Sales Agent
Indemnitees”) from all Liabilities which any Sales Agent Indemnitee may incur by reason of any Products sold or furnished by Company which result in injury, illness or death to the extent that such Liabilities arise out of or result from the
failure of the Products to meet the Product warranty set forth in Section 17 or the recklessness, gross negligence, or willful misconduct of any Company Indemnitee. 
  

 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 12.3. The party seeking indemnification hereunder (the “Indemnified Party”) shall:
(i) give the other party (the “Indemnifying Party”) notice of the relevant claim, (ii) cooperate with the Indemnifying Party, at the Indemnifying Party’s expense, in the defense of such claim and (iii) give the
Indemnifying Party the right to control the defense and settlement of any such claim, except that the Indemnifying Party shall not enter into any settlement that affects the Indemnified Party’s rights or interest without the Indemnified
Party’s prior written approval. The Indemnified Party shall have no authority to settle any claim on behalf of the Indemnifying Party. 
  

	13.	CONFLICTS OF INTEREST 

 During the term of this
Agreement, Sales Agent covenants that neither it nor any Sales Agent Indemnitee will engage directly or indirectly in any activity which materially conflicts with Sales Agent’s faithful performance of the services covenants, commitments and
obligations undertaken to be performed pursuant to this Agreement. 
  

	14.	CONFIDENTIAL INFORMATION 

 14.1. Sales Agent
acknowledges that it will have access to certain Confidential Information (as defined below) relating to the Company or its business, including, but not limited to the internal organization of the Company; the names and responsibilities of its
management, supervisory and technical employees, operating plans, Inventions (as defined below), research and development activities, plans for acquisitions and mergers, manufacturing and/or sales activities, technical information concerning
Products and related instrumentation, trade secrets, specifications, procedures, techniques, ideas, methods, Patents (as defined below) and the names of customers and suppliers (the “Confidential Information”). 
 14.2. Sales Agent covenants that it will hold all Confidential Information confidential and shall only use such Confidential Information to satisfy its
obligations under this Agreement. During the term of this Agreement Sales Agent will be permitted, however, to disclose such part of the Confidential Information to those of its employees and/or agents as is necessary to be known by them to assist
or enable Sales Agent to perform its services and obligations under this Agreement, provided that such employee or agent has entered into a written agreement of confidentiality, the terms of which are no less rigorous than the terms set forth in
this Section 14. 
 14.3. The restrictions on use and disclosure of Confidential Information set forth in this Section 14 shall not
apply: (i) to the extent that the Confidential Information is in the public domain without fault on the part of Sales Agent or any third party not bound by an obligation of confidentiality; or (ii) disclosures that are mandated by court of
competent jurisdiction, provided that Sales Agent notifies the Company prior to such disclosure and takes reasonable actions to limit the disclosure of such Confidential Information. 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 14.4. Upon the Company’s written demand or upon expiration or termination of this Agreement,
Sales Agent, at its own cost and expense, will promptly return all Confidential Information to the Company to the extent held or controlled by Sales Agent in written, graphic or other tangible form, and all copies, summaries, notes and other
write-ups thereof made by Sales Agent, or its employees and agents. 
 14.5. The obligations set forth in this Section 14 shall survive
the termination or expiration of this Agreement. 
  

	15.	TERM AND TERMINATION 

 15.1. This Agreement will
become effective on the Effective Date and will continue until the [***] anniversary of the Effective Date. Upon the written agreement of the parties, this agreement may be extended for additional one-year terms. 
 15.2. This Agreement may be terminated by the Company as follows: (i) at any time upon [***] days’ written notice from the Company to the Sales
Agent; (ii) at any time during the term of this Agreement if Sales Agent fails to meet its sales quotas; (iii) at any time if Sales Agent engages in behavior that, in the Company’s reasonable determination, is materially detrimental
to the Company or its business reputation, including without limitation, a determination in the Company’s sole reasonable discretion that Prescribers have acquired too large of a percentage of the Sales Agent’s equity securities;
(iv) at any time if Sales Agent becomes insolvent or bankrupt, or files a voluntary petition in bankruptcy, or has filed for an involuntary petition in bankruptcy; or (v) at any time following the end of a 15-day cure period if Sales Agent
fails to cure any breach of a covenant, commitment or obligation under this Agreement within 15 days after receipt of written notice from the Company of such breach. 
 15.3. This Agreement may be terminated by Sales Agent as follows: (i) at any time if the Company becomes insolvent or bankrupt, or files a voluntary petition in bankruptcy, or has filed for an involuntary
petition in bankruptcy; or (ii) at any time following the end of a 15-day cure period if the Company fails to cure any breach of a covenant, commitment or obligation under this Agreement within 15 days after receipt of written notice from the
Company of such breach. 
 15.4. Following the termination or expiration of this Agreement: (i) Sales Agent shall discontinue all
promotion and distribution of the Products in the Territory; (ii) Sales Agent will not be entitled to any commissions on sales of the Products that are invoiced in the Territory after the effective date of expiration or termination of this
Agreement; (iii) the Company and Sales Agent will undertake to reconcile all matters pertaining to commission and other amounts, if any, owed by either party to the other up to the effective date of expiration or termination, as promptly as
practicable thereafter, and will settle accounts between them (including without limitation the return of all Consigned Inventory in accordance with this Agreement) in good faith not later than 60 days after the effective date of expiration or
termination of this Agreement. 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

	16.	INTELLECTUAL PROPERTY 

 16.1. Except as granted in
this Agreement, Sales Agent has no rights in or to the Company’s trademarks, or any other trademarks, trade names or copyrights owned or used by Company (the “Trademarks”) and Sales Agent agrees that it shall not in any way infringe
upon, harm, contest or otherwise impair the rights of Company to the Trademarks. All material containing Trademarks, including all Samples, shall be used solely in connection with promoting the sale of Products, and distinguishing and identifying
them. Sales Agent may not use any Trademarks in its corporate title or the corporate title of any entity it controls. If it becomes necessary, because of conflicts with trademarks or trade names used by third parties, to develop non-conflicting
marks and names for certain parts of the Territory, Sales Agent shall so inform Company, and such new marks and names shall be developed by Company, and shall belong to Company, subject to Sales Agent’s license to use them pursuant to the terms
of this Section 16. The Company, on behalf of itself and its subsidiaries, hereby grants to Sales Agent a non-exclusive, non-transferable limited license to use the Trademarks solely in connection with its promotion, marketing and sales of the
Products in the Territory pursuant to the terms of this Agreement. Sales Agent shall have no further rights or interest in any such Trademarks. 
 16.2. Sales Agent acknowledges and agrees that any patent on the Products acquired by the Company or any of its subsidiaries and any patent applications on the Products filed by the Company or any of its subsidiaries (the
“Patents”) are the sole and exclusive property of the Company and that throughout the term of this Agreement and following its termination or expiration, Sales Agent will not do anything inconsistent with such ownership, will not directly
or indirectly challenge the title of the Company or any of its subsidiaries to the same and will not attack the validity of such Patents. 
 16.3. Sales Agent agrees to promptly notify the Company of any unauthorized use of the Trademarks or infringement of the Patents by others as it comes to Sales Agent’s attention. 
 16.4. Sales Agent shall submit to the Company all inventions, discoveries and ideas concerning any modifications and improvements relating to the
Products and related instrumentation (the “Inventions”). Further, all such Inventions are, and shall remain, the sole property of the Company. Sales Agent hereby assigns to the Company all of its rights, title and interest to Inventions,
and shall take such actions as is necessary to vest such rights and interests in the Company and shall require its employees and agents to take similar actions to vest ownership of such Inventions in the Company. 
  

	17.	LIMITED WARRANTY. 

 The Company warrants that, under
normal use and service and when used in accordance with specifications supplied by Company, the Products will be of merchantable quality. If any Products do not comply with such warranty, Company will, at its option and expense, correct, repair, or
replace any defective Products provided, that, in all such cases that sufficient evidence is produced by Sales Agent to establish that the Products are defective. THE COMPANY 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
MAKES NO OTHER WARRANTIES, EXPRESSED OR IMPLIED, WITH RESPECT TO THE PRODUCTS AND ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE
ARE EXPRESSLY AND SPECIFICALLY EXCLUDED AND DISCLAIMED. 
  

	18.	LIMITATION OF LIABILITY. 

 THE COMPANY’S
LIABILITY UNDER THE WARRANTY SET FORTH IN SECTION 17 OR OTHERWISE WITH RESPECT TO THE PRODUCTS OR THEIR USE (INCLUDING LIABILITY FOR CONTRACT, NEGLIGENCE OR OTHERWISE IN TORT) IS LIMITED EXCLUSIVELY TO THE REMEDY PROVIDED IN SECTION 12, AND NO OTHER
RIGHT OR REMEDY WILL BE AVAILABLE TO ANY PERSON. IN NO EVENT WILL THE COMPANY BE LIABLE TO THE SALES AGENT OR ANY OTHER PERSON OR ENTITY FOR ANY SPECIAL, INDIRECT, EXEMPLARY, PUNITIVE, INCIDENTAL OR CONSEQUENTIAL DAMAGES TO PERSON OR PROPERTY OR
LOSS OF PROFITS OF ANY PERSON RESULTING FROM ANY CAUSE WHATSOEVER, EVEN IF COMPANY HAS BEEN ADVISED, KNEW OR SHOULD HAVE KNOWN OF THE POSSIBILITY OF SUCH DAMAGES OR LOSS OF PROFITS. SOME STATES AND JURISDICTIONS OUTSIDE OF THE UNITED STATES DO NOT
ALLOW A LIMITATION OR EXCLUSION OF IMPLIED WARRANTIES, OR LIABILITY FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES, SO THE ABOVE LIMITATION OR EXCLUSION MAY NOT APPLY. SALES AGENT ACKNOWLEDGES THAT THE ALLOCATION OF RISKS AND BENEFITS UNDER THIS AGREEMENT
IS BASED ON, AND THE AMOUNTS PAID UNDER THIS AGREEMENT WOULD BE GREATER IN THE ABSENCE OF, THE LIMITATIONS DESCRIBED ABOVE. 
  

	19.	MISCELLANEOUS PROVISIONS 

 19.1. This Agreement
contains the entire agreement and understanding between the parties respecting the subject matter hereof, and supersedes all prior and collateral agreements and understandings, regardless of form or nature between the parties respecting that subject
matter. 
 19.2. Other than as explicitly set forth in this Agreement, no extension, modification or supplement to this Agreement will be
effective unless made in writing and signed by a duly authorized officer of each party. 
 19.3. This Agreement will be binding upon Sales
Agent, the Company and their respective successors and permitted assigns. 
 19.4. Any notice required, permitted or contemplated by this
Agreement must be in writing, sent by facsimile, or nationally recognized overnight carrier, addressed to the other party as set forth below, or to such other address as may from time to time be substituted therefore by notice, or delivered in
person to such other party. Except as otherwise provided in this Agreement, notices sent by facsimile will be effective on the date that written confirmation of the 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
transmission of the facsimile is received by the sender and notices sent by overnight carrier shall be effective on the business day following written
confirmation of delivery of the notice to such carrier. For purposes of notices, the addresses of the parties will be: 
  

							
	If to the Company:	    	Alphatec Spine, Inc.	  	
		    	2051 Palomar Airport Road, Ste 100	  	
		    	Carlsbad, CA 92011	  	
		    	Attention: Vice President, Sales	  	
		    	Phone: 760 431 9286	  	
		    	Facsimile: 760 431 1624	  	
			
	If to Sales Agent:	    	Fusion Medical, Inc.	  	
		    	309 North Sea Lake Lane	  	
		    	Ponte Vedra Beach, FL 32082	  	
		    	Attn: Greg Smith	  	
		    	Phone: 904 509-6030	  	
		    	Facsmile: 904 273-9133	  	

 19.5. Except as provided for within this Agreement, no delay or failure by either party to enforce
or take advantage of any provision of this Agreement for non-performance or breach of any obligation hereunder by the other party, or to exercise any right hereunder, will constitute a waiver of the right of such party subsequently to enforce or
take advantage of such provision or any other provisions hereof (unless performance has been resumed or the breach has been cured by the other party) or to exercise such right or any other right hereunder, unless such waiver is in writing signed by
a duly authorized officer of the party against whom the waiver is claimed to apply, or unless the respective period for enforcement, taking advantage or exercise, as the case may be, has expired by the express terms of this Agreement. 
 19.6. This Agreement may not be assigned by Sales Agent except with the written consent of the Company and any assignment that occurs without proper
consent shall be deemed to be null and void. For the purposes of this Section 19.6, a merger of the Sales Agent with or into another entity, the sale of more than fifty percent (50%) of the Sales Agent’s equity securities in one or a
series of transactions, or the sale of substantially all of the Sales Agent’s assets shall be deemed to be an assignment. The Company may assign this Agreement by giving written notification to the Sales Agent. 
 19.7. The parties agree that the breach of this Agreement may cause irreparable harm to a party. Therefore, in addition to the other remedies specified
herein, either party may enforce its rights hereunder by all available equitable remedies, including, without limitation, the right to obtain an injunction or specific performance. 
 19.8. The Company shall not be responsible for any failure or delay in performance of its obligations under this Agreement because of circumstances
beyond its reasonable control, including, without limitation, acts of God, fires, floods, wars, civil disturbances, sabotage, 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
accidents, labor disputes (whether or not the employees’ demands are reasonable and within the Company’s power to satisfy), governmental actions or
inability to obtain labor, material, equipment or transportation, nor shall any such failure or delay give the Sales Agent any right to terminate this Agreement. If any delivery or shipment of Products is delayed because of any such circumstance, it
shall be made as soon as possible. 
 19.9. This Agreement may be executed in multiple counterparts, each of which will constitute an
original, but all of which together will constitute one and the same Agreement. 
 19.10. Notwithstanding the expiration or termination of
this Agreement for any reason, rights and obligations which by the nature should survive will remain in full force and effect. In particular the following sections shall survive the expiration or termination of this Agreement: Section 2.3,
Section 2.4, Section 2.6, Section 2.7, Section 7.8, Section 12, Section 14, Section 15.4, Section 16, Section 17, Section 18, Section 19.4, Section 19.7, Section 19.10,
Section 19.11 and Section 19.12. 
 19.11. The validity, construction and enforcement of this Agreement and all matters related
thereto or in connection therewith all be governed by the laws of the state of California and the venue of any action brought shall be in San Diego County, California. 
 19.12. If any provision of this Agreement is rendered or declared unlawful by reason of any existing or subsequently enacted law or by decree or order of a court of last resort, the remaining provisions of this
Agreement will continue in full force and effect. 
 * * * 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and year first above
written. 
  

			
	ALPHATEC SPINE, INC.
		
	By:	 	 /s/ M. Ross Simmonds

	Name:	 	M. Ross Simmonds
	Title:	 	Senior Vice President and Chief Operating Officer
	
	FUSION MEDICAL, INC.
	
	 /s/ Greg Smith

	Name:	 	Greg Smith
	Title:	 	President

  
 CONFIDENTIAL TREATMENT REQUESTED

 CONFIDENTIAL TREATMENT REQUESTED 
  

 EXHIBIT A 
 PRODUCTS 
 [***] 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 EXHIBIT B 
 LIST OF SALES AGENT’S TERRITORY 
 [***] 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 EXHIBIT C 
 COMMISSION RATE 
 [***] 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 EXHIBIT D 
 SALES QUOTAS 
 [***] 
  

CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 EXHIBIT E 
 FORM OF HOSPITAL CONSIGNMENT AGREEMENT 
 Alphatec Spine, Inc. Inventory Consignment
Agreement 
 This Inventory Consignment Agreement (the “Agreement”) is between Alphatec Spine, Inc., a California
corporation (the “Company”) and the medical institution listed on the signature page below (the “Institution”) is made as of
                         , 200     (the “Effective Date”). 
 WHEREAS the Company and the Institution have agreed to have certain of the Company’s inventory (including all related instrumentation) (the
“Consigned Inventory”) stocked at the Institution pursuant to the terms of this Agreement. 
 NOW THEREFORE, in consideration of
the mutual covenants and provisions herein contained, the adequacy of which is hereby satisfied, the parties agree as follows: 
 1. Listed
below is all of the Consignment Inventory: 
  

			
	 Item Description
	  	 Quantity

		  	
		  	
		  	
		  	
		  	
		  	
		  	
		  	
		  	
		  	

 2. Institution will hold said Consigned Inventory in a fiduciary capacity under a separate account
titled “Consigned Inventory”. 
 3. Institution shall not use the Consigned Inventory for any other purpose other than with the
consent of the Company or its authorized employees or agents. 
 4. At any time during the term of this Agreement, the Company may request a
physical inventory of the Consigned Inventory by the Institution and the Institution shall promptly respond to such request. 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 5. If any Consigned Inventory is returned damaged, then the Company, to the extent possible, will
repair or refurbish the Consigned Inventory and invoice the Institution for the cost of said repairs and handling. If the damaged Consigned Inventory cannot be repaired, then the Company shall invoice the Institution for 100% of the list price of
such Consigned Inventory. If any Consigned Inventory is lost, missing or stolen, then the Company shall invoice the Institution for 100% of the list price of such Consigned Inventory. In each of the instances set forth in this Section 5, upon
receipt of such invoice, Institution shall promptly remit payment to the Company. 
 6. Either party may terminate this agreement at any time
by providing written notice to the other party; provided that Section 5 and Section 7 shall survive the termination of this Agreement. 
 7. Upon the termination or expiration of this Agreement, the Institution shall immediately, and at its own expense, return all Consignment Inventory in its possession or control to the Company. 
 *        *        * 
 IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and year first above written. 
  

			
	COMPANY:
	
	ALPHATEC SPINE, INC.
		
	By:	 	  

	Name:	 	
	Title:	 	

			
		
	INSTITUTION:	 	
		
	(print name of Institution)	 	  

			
		
	By:	 	  

	Name (please print):
	Title:	 	

  
 CONFIDENTIAL TREATMENT REQUESTEDLicense Agreement by and between Alphatec Spine

 CONFIDENTIAL TREATMENT REQUESTED 
  

 Exhibit 10.29 
 EXCLUSIVE LICENSE AGREEMENT 
 This Exclusive License Agreement (this “Agreement”) is made
effective as of December 18, 2007 (the “Effective Date”) by and among Alphatec Spine, Inc., a Delaware corporation with a principal place of business at 2051 Palomar Airport Road, Suite 100, Carlsbad, California 92008
(“Licensee”), Progressive Spinal Technologies LLC, a limited liability company organized under the laws of the state of Delaware, with an address at 410 East Walnut Street, Suite #8, Perkasie, Pennsylvania 18944 (“Licensor”) and
for purposes of Section 7.2 and Section 11.15 hereof only Alphatec Holdings, Inc., a Delaware corporation with a principal place of business at 2051 Palomar Airport Road, Suite 100, Carlsbad, California 92008 (“Holdings”).
Licensee and Licensor are each hereafter referred to individually as a “Party” and together as the “Parties”. 
 WHEREAS,
Licensor is the owner of or otherwise controls certain proprietary Licensed Patents and Licensed Technology (as defined below); and 
 WHEREAS, Licensee desires to obtain a license from Licensor under such Licensed Patents and Licensed Technology to develop and commercialize Licensed Products (as defined below); and 
 WHEREAS, Licensor desires to grant such license to Licensee on the terms and subject to the conditions of this Agreement. 
 NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and adequacy of
which are hereby acknowledged, the Parties hereby agree as follows. 
 1. DEFINITIONS 
 Whenever used in the Agreement with an initial capital letter, the terms defined in this Article 1 shall have the meanings specified. 
 1.1 “Affiliate” shall mean any company, corporation, partnership, limited liability company, trust, or other business entity that
directly or indirectly controls, is controlled by, or is under common control with a designated person or entity, and for such purpose “control” shall mean the possession, direct or indirect, of the power to direct or cause the direction
of the management and policies of the entity, whether through the ownership of voting securities, by contract or otherwise. 
 1.2 [***].

 1.3 “Common Stock” shall mean the common stock of Holdings, and any securities into which such common stock may
hereafter be reclassified, converted or exchanged. 
 1.4 “Confidential Information” shall mean with respect to a
Party (the “Receiving Party”), all information which is disclosed by the other Party (the “Disclosing Party”) to the Receiving Party hereunder or to any of its employees, consultants, Affiliates, 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
licensees or sublicensees, except to the extent that the Receiving Party can demonstrate by written record or other suitable physical evidence that such
information, (a) as of the date of disclosure is demonstrably known to the Receiving Party or its Affiliates other than by virtue of a prior confidential disclosure to such Party or its Affiliates; (b) as of the date of disclosure is in,
or subsequently enters, the public domain, through no fault or omission of the Receiving Party; (c) is obtained from a Third Party having a lawful right to make such disclosure free from any obligation of confidentiality to the Disclosing
Party; or (d) is independently developed by or for the Receiving Party without reference to or reliance upon any Confidential Information of the Disclosing Party. Any information in relation to the subject matter of this Agreement disclosed by
a Party under that certain Mutual Confidentiality Agreement between the parties dated the 10th day of August 2007 shall, subject to the foregoing exceptions, be considered Confidential Information for purpose of this Agreement. 
 1.5 “First Commercial Sale” shall mean the date of the first transaction, transfer or disposition for value by or on behalf of
Licensee or any Affiliate or Sublicensee of Licensee to a Third Party of a Licensed Product in the United States following the applicable regulatory clearance by the FDA (as defined below). 
 1.6 “FDA” shall mean the United States Food and Drug Administration and any successor agency or authority thereto. 
 1.7 “Guarantee and Agreement” shall mean the guarantee and agreement of Holdings set forth in Section 11.15 hereof.

 1.8 “Joint Inventions” shall have the meaning given in Section 3.3. 
 1.9 “Licensor Indemnitees” and “Licensee Indemnitees” (each individually an
“Indemnitee”) shall have the meaning given in Section 8.1. 
 1.10 “Licensed Field”
shall mean [***]. 
 1.11 “Licensed Patent Rights” shall mean any of the patent applications described in Schedule
A attached hereto, and any divisional, continuation, continuation-in-part (to the extent that the continuation-in-part is entitled to the priority date of an initial patent or patent application which is the subject of this Agreement), reissue,
reexamination, registration, renewal, or extension, or any patent issuing therefrom or any supplementary protection certificates related thereto, and any foreign counterparts to any of the foregoing. 
 1.12 “Licensed Product” shall mean any product sold by Licensee, its Affiliates or Sublicensees that embodies or uses any aspect
of the Licensed Patent Rights and/or the Licensed Technology. 
 1.13 “Licensed Technology” shall mean all Technology
which: 
 1.13.1 Licensor controls as of the Effective Date and which (i) is described in or related to any patent or patent
application included in the Licensed Patent Rights and (ii) is necessary or useful for Licensee to practice the license granted to it hereunder; 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 1.13.2 is developed by Licensor as a part of its efforts contemplated by Section 3.2;

 1.13.3 Licensor controls after the Effective Date but during the Term and which (i) it has the right to disclose and license without
the payment of royalties or other consideration to any Third Party and (ii) constitutes an improvement to the subject matter of the Licensed Patent Rights or Licensed Technology as it exists on the date of determination, including
Licensor’s interest in any Joint Inventions; and/or 
 1.13.4 Licensee controls after the Effective Date but during the Term and which
constitutes an improvement to the subject matter of the Licensed Patent Rights or Licensed Technology as it exists on the date of determination. 
 1.14 “Market Launch” shall mean the first national commercial launch of any Licensed Product. 
 1.15
“Net Sales” shall mean the gross amount invoiced or otherwise payable by Licensee, any of its Affiliates or any Sublicensee on account of sales or other transfers of a Licensed Product anywhere in the Territory during a
designated period, less (to the extent otherwise then or previously included in amounts invoiced for such Licensed Product and in respect of which no previous deduction was taken): 
 1.15.1 trade, cash and quantity discounts or rebates actually allowed or taken on Licensed Products, including discounts or rebates to governmental or
managed care organizations; 
 1.15.2 credits or allowances actually given or made for rejection of, and for uncollectible amounts (except
to the extent later collected) on, or return of previously sold Licensed Products; 
 1.15.3 any charges for insurance, freight, and other
transportation costs directly related to the delivery of Licensed Product to the extent included in the gross invoiced sales price; 
 1.15.4 any tax, tariff, duty or governmental charge levied on the sales, transfer, transportation or delivery of a Licensed Product (including any tax such as a value added or similar tax or government charge), other than franchise or
income tax of any kind whatsoever; and 
 1.15.5 any import or export duties or their equivalent borne. 
 In addition, should Licensee be required, in order to lawfully exercise its rights as to a Licensed Product, obtain additional rights in a country to patents of any
Third Parties which are not Affiliates of Licensee, which patents are (i) pending or issued on the Effective Date, and (ii) required for Licensee to practice the inventions described in the Licensed Patent Rights or 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
Licensed Technology or exercise the license granted under this Agreement for reasons not attributable to a design selection made by Licensee for which
alternative design selections not requiring such additional rights are available, then Licensee may also deduct from Net Sales with respect to a designated period the amount of the royalty Licensee is required to pay to such Third Party or Parties
for such necessary rights to such patents with respect to such Licensed Product; provided that in no event (i) shall the amount of Net Sales for any designated period be reduced by more than [***] percent ([***]%) on account of royalties paid
to Third Parties, and any amount so disallowed shall be lost and not carried forward and (ii) no such reduction shall be permitted with respect to additional rights obtained more than [***] ([***]) years after the First Commercial Sale in such
country. 
 “Net Sales” shall not include amounts invoiced to or otherwise payable by Licensee, any of its Affiliates and/or any Sublicensees for
Licensed Products sold or otherwise transferred to Licensee or any of its Affiliates and/or its Sublicensees, unless the Licensed Product is consumed by the invoiced entity. 
 1.16 “Shares” shall have the meaning set forth in Paragraph 4.4.1(a) hereof. 
 1.17 “Sublicensee” shall mean any Third Party to whom Licensee grants a sublicense of some or all of the rights granted to
Licensee under this Agreement. 
 1.18 “Technology” shall mean all of the following intangible legal rights, whether
or not filed, perfected, registered or recorded, applicable to the Licensed Field: (i) inventions, patents, patent disclosures, patent rights, including any and all continuations, continuations-in-part, divisionals, reissues, reexaminations,
utility models, industrial designs and design patents or any extensions thereof, (ii) rights associated with works of authorship, including without limitation, copyrights, copyright applications and copyright registrations and (iii) any
and all proprietary ideas, inventions, discoveries, Confidential Information, data, results, formulae, designs, specifications, methods, processes, techniques, ideas, know-how, technical information (including, without limitation, structural and
functional information), process information, pre-clinical information, clinical information, and any and all proprietary control and manufacturing data and materials, whether or not patentable. 
 1.19 “Term” shall have the meaning given in Section 9.1. 
 1.20 “Territory” shall mean all countries and jurisdictions of the world. 
 1.21 “Third Party” shall mean any person or entity other than Licensee, Licensor and their respective Affiliates. 
 2. GRANT OF RIGHTS 
 2.1 License
to Licensee. 
 2.1.1 Grant of License. Licensor hereby grants to Licensee an exclusive (even as to Licensor and its
Affiliates), royalty-bearing license, including the right to grant 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
sublicenses in accordance with Subsection 2.1.2, under the Licensed Patent Rights and Licensed Technology: (i) to conduct research and development in
support of the licensed uses describe in clause (ii) of this Subsection, and (ii) to make, have made, import, export, use, offer for sale or sell Licensed Products in the Licensed Field, subject to the terms and conditions of this
Agreement. 
 2.1.2 Right to Sublicense. Licensee shall have the right to grant sublicenses, subject to the terms of this Agreement,
to all or any portion of its rights under the license granted pursuant to this Subsection. 
 2.2 Right of First Discussion in Relation
to Sales of Licensed Patent Rights or Licensed Technology. In the event that Licensor decides to sell any of the Licensed Patent Rights or Licensed Technology (subject, of course, to this Agreement), it shall give prompt notice
thereof to the Licensee. Such notice shall include a description of the Licensed Patent Rights or Licensed Technology to be sold. Thereafter, Licensee shall have sixty (60) days to notify Licensor whether Licensee is interested in commencing
negotiations to obtain a fully-paid license to such Licensed Patent Rights or Licensed Technology in the Licensed Field. If Licensee does not give such notice within such sixty (60) day period, Licensor shall be entitled to sell such Licensed
Patent Rights or Licensed Technology as it sees fit. If Licensee gives such written notice within such sixty (60) days, the parties shall for a further sixty (60) days from the giving of such notice, or such longer time period as upon
which the Parties mutually agree in writing, negotiate in good faith as to the terms of such fully-paid license in the Licensed Field, and Licensor shall not be entitled to commence negotiations with any Third Party with respect to the sale of such
Licensed Patent Rights or Licensed Technology, or sell such Licensed Patent Rights or Licensed Technology, until the end of such sixty (60) day or longer agreed-upon period, after which it shall be free to negotiate or sell such intellectual
property as it sees fit. 
 2.3 Right of First Discussion as to New In-Field License. If, at any time during the term of the
Agreement, Licensor acquires or develops intellectual property in respect of uses or applications within the Licensed Field (a “New In-Field Use”) which is not included in the Licensed Technology and which Licensor has the right to
disclose and license without the payment of royalties or other consideration to any Third Party, it shall give prompt notice thereof to the Licensee. Such notice shall include a description of the intellectual property which Licensor has acquired or
developed. Thereafter, Licensee shall have sixty (60) days to notify Licensor whether Licensee is interested in commencing negotiations to obtain a license to such rights (the “New In -Field License”). If Licensee does not give such
notice within such sixty (60) day period, Licensor shall be entitled to license such intellectual property as it sees fit. If Licensee gives such written notice within such sixty (60) days, the parties shall for a further sixty
(60) days from the giving of such notice, or such longer time period as upon which the Parties mutually agree in writing, negotiate in good faith as to the terms of such New In-Field License, and Licensor shall not be entitled to commence
negotiations with any Third Party in respect to a license of such intellectual property, or license such intellectual property, within the Licensed Field until the end of such sixty (60) day or longer agreed-upon period, after which it shall be
free to negotiate or license such intellectual property as it sees fit. For the sake of clarity, this Section 2.2 does not apply to any intellectual property that is included in Licensed Technology and, as such, is subject to the license grant
under Section 2.1. 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 3. DEVELOPMENT AND COMMERCIALIZATION OF LICENSED PRODUCTS. 
 3.1 Commercialization. 
 3.1.1
Responsibility. From and after the Effective Date, Licensee shall have full control and authority over the development and commercialization of Licensed Products in the Licensed Field in the Territory. Without prejudice to Section 3.3
hereof, Licensee shall own all Technology resulting solely from the efforts of its agents, Affiliates and employees as a part of such development and commercialization, but for such purposes (or any other purpose of this Agreement) Licensor shall
not be considered an agent of Licensee. Except as set forth on Exhibit B hereto, all activities relating to development and commercialization under this Agreement shall be undertaken at Licensee’s sole cost and expense. 
 3.1.2 Diligence. After the Effective Date, Licensee will exercise commercially reasonable efforts to develop a Licensed Product which will pass
[***], and thereafter cause the Market Launch of the first Licensed Product as soon as practicable, such commercially reasonable efforts to take into account the competitiveness of the marketplace, the proprietary position of the Licensed Product,
the relative potential safety and efficacy of the Licensed Product, the cost of goods and availability of capacity to manufacture and supply the Licensed Product at commercial scale, the profitability of the applicable Licensed Product, and other
relevant factors including, without limitation, technical, legal, scientific or medical factors. 
 3.2 Licensor Assistance.
Prior to the First Commercial Sale of a Licensed Product, Licensor agrees that it shall provide commercially reasonable assistance to the Licensee in connection with the development and commercialization of a Licensed Product as such assistance
is described in Schedule B hereto in exchange for the compensation also described in Schedule B. Licensor will use commercially reasonable efforts to identify one (1) surgeon that participated in the Licensor’s development of
the Licensed Technology who will agree, at Licensee’s expense, to be a member of the Licensee’s design team on the development of a Licensed Product. Licensor shall own all Technology resulting solely from the efforts of the agents,
Affiliates and employees of Licensor as a part of such development and commercialization, (but for such purposes (or any other purpose of this Agreement) Licensee shall not be considered an agent of Licensor), but such Technology shall be deemed
included in the Licensed Technology. 
 3.3 Joint Inventions. Technology conceived, developed or reduced to practice jointly by
employees or consultants of Licensor and Licensee during the term hereof shall be jointly owned by them (“Joint Inventions”). For purposes of this Section 3.3 Technology that is the subject of a patent application shall be deemed to
have been developed jointly by employees or consultants of Licensee and Licensor, and thus be a Joint Invention, if at least one employee or consultant of each of Licensee and Licensor is required to be named as an inventor in such application in
order for such patent to be valid, and a comparable concept 
  
 CONFIDENTIAL
TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
shall apply to Technology not the subject of a patent application. Subject to its right of abandonment or other forfeiture, Licensee shall be responsible, at
its costs, for preparing, filing and, prosecuting patent applications which are available with respect to Joint Inventions in the United States, Japan, Germany, the United Kingdom, France, Spain and Italy (and elsewhere as it may elect), using
patent counsel reasonably chosen by Licensee, and for maintaining any patents obtained thereon. Licensee shall keep Licensor reasonably appraised as to the prosecution of each such patent application. Licensee agrees to send Licensor copies of all
file histories and prosecution documents for each of the patent applications of the Licensed Patent Rights, within thirty (30) days of receipt by Licensor. Licensee shall have the right in its discretion to abandon or otherwise cause or allow
to be forfeited, any patents or applications therefore as to Joint Inventions. Licensee shall give Licensor at least sixty (60) days written notice prior to abandonment or other forfeiture so as to permit, but not obligate, Licensor, to file,
in the name of Licensor, for protection as to such patent or application, at its cost and expense, and Licensee shall have no interest in such patent or applications or underlying Joint Inventions (which shall thereupon cease to be Joint Inventions
by shall rather be Confidential Information of Licensor). In any event each Party will, and will cause its employees and consultants to, provide any assistance and executed agreements and instruments as are reasonably requested by a Party which is
seeking to obtain in accordance herewith patents or other protection with respect to any Joint Inventions. 
 3.4 Licensee License
Grant. Licensee hereby grants to Licensor: 
 3.4.1 Non-exclusive License. a non-exclusive, fully-paid and
royalty-free, perpetual license, including the right to grant sublicenses, under all Technology owned by Licensee as a result of the activities set forth in Section 3.1: (i) to conduct research and development in support of the licensed
uses describe in clause (ii) of this Subsection, and (ii) to make, have made, import, export, use, offer for sale or sell any component or product for indications outside of the treatment of spinal disorders, subject to the terms and
conditions of this Agreement; and 
 3.4.2 Exclusive License. an exclusive, fully-paid and royalty-free, perpetual license, including
the right to grant sublicenses, under its interest in all Joint Inventions: (i) to conduct research and development in support of the licensed uses describe in clause (ii) of this Subsection, (ii) to make, have made, import, export,
use, offer for sale or sell any component or product for indications outside of the treatment of spinal disorders, subject to the terms and conditions of this Agreement, and (iii) to prosecute at Licensor’s sole cost and for its sole
benefit infringements of Joint Inventions within the scope of the licenses granted in clauses (i) and (ii) of this Subsection 3.4.2. 
 4. PAYMENTS AND ROYALTIES 
 4.1 Initial Payment; Milestone Payments, Payment of Royalties; Royalty Rates; Minimum
Royalties; Milestone Payments.  
  
 CONFIDENTIAL TREATMENT
REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 4.1.1 Initial Payment. Licensee shall pay Licensor a lump-sum, payment of [***] dollars
($[***]) (the “Initial Payment”) within ten (10) business days of the Effective Date. The Initial Payment shall be fully-earned and non-refundable. 
 4.1.2 Milestone Payments. Licensee shall pay milestone payments (or in the case of the Common Stock cause the issuance thereof by Holdings) to Licensor (each such payment or issuance a “Milestone
Payment”) as specified below no more than thirty (30) days after the occurrence of the corresponding event designated below, unless this Agreement has been terminated prior to such due date. No Milestone Payments described in this
Subsection 4.1.2 shall be credited against or otherwise reduce any other amounts payable hereunder. 
  

			
	 Event
	  	 Milestone Payment

	 [***]
	  	[***]
		
	 [***]
	  	[***]
		
	 [***]
	  	[***]
		
	 [***]
	  	[***]
		
	 [***]
	  	[***]

 4.1.3 Royalty Payments. During the Term, Licensee shall pay to Licensor within thirty
(30) days of the end of each calendar quarter earned royalties of [***] percent ([***]%) of Net Sales during such calendar quarter. Each royalty payment shall (i) be accompanied by a report specifying: the Net Sales (including an
accounting of deductions taken in the calculation of Net Sales) and (ii) state the applicable exchange rate used in conversion from any foreign country’s currency to United States Dollars (which conversion shall be determined in accordance
with Subsection 4.2.2). Earned royalties described in this Subsection 4.1.3 shall only be credited against minimum royalties which would otherwise be due as contemplated by Subsection 4.1.4 and shall not be credited against or otherwise reduce any
other amounts payable hereunder. 
 4.1.4 Minimum Royalties. Licensee shall pay Licensor the following minimum annual royalty amounts
in each calendar year listed next to such amount. No minimum annual royalty described in this Subsection 4.1.4 shall be credited against or otherwise reduce any other amounts payable hereunder. For a particular calendar year, in the event
that the sum of the earned royalties on Net Sales timely paid in accordance with Subsection 4.1.3 above with respect to the four calendar quarters of such calendar year are less than the minimum annual royalty for such year designated below, the
obligation to pay the difference to Licensor shall accrue on the last day of such calendar year and be payable by Licensee no later than forty-five (45) days following the end of such calendar year: 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

			
	 Twelve (12) Months Ending
	  	 Minimum Annual Royalty

	 December 31, 2009
	  	[***]
		
	 December 31, 2010
	  	[***]
		
	 December 31, 2011
	  	[***]
		
	 December 31, 2012 and each calendar year thereafter
	  	[***]

 4.1.5 One Royalty. Only one royalty shall be payable to Licensor hereunder for each sale
of a Licensed Product, notwithstanding that more than one patent or patent claim reads upon such Licensed Product and/or such Licensed Product embodies or was made using one or more aspects of Licensed Technology. 
 4.2 Payment, Conversion and Withholding. 
 4.2.1 Payment. All payments hereunder shall originate in the United States and be made in United States dollars and be paid to Licensor by wire transfer at the account designated below (or by other means
reasonably selected by Licensor and delivered to Licensee in writing with no less than ten (10) days prior written notice): routing: [***]. 
 4.2.2 Conversion. Conversion of foreign currency to United States dollars shall be made at the conversion rate existing in the United States (as reported in The Wall Street Journal) on the last business day of the quarter
immediately preceding the applicable calendar quarter. If The Wall Street Journal ceases to be published, then the rate of exchange to be used shall be that reported in such other business publication of national circulation in the United
States as the Parties reasonably agree.  
 4.2.3 Tax Withholding; Restrictions on Payment. All taxes, assessments and fees of
any nature levied or incurred on account of any payments from Licensee to Licensor accruing under this Agreement, by national, state or local governments, will be assumed and paid by Licensee, except taxes levied thereon as income to Licensor and if
such taxes are required by applicable law to be withheld by Licensee they will be deducted from payments due to Licensor and will be timely paid by Licensee to the proper taxing authority for the account of Licensor, a receipt or other proof of
payment therefore secured and sent to Licensor as soon as practicable. Licensee shall remit all payments to Licensor hereunder from within the United States. 
 4.3 Records Retention; Review. 
 4.3.1 Royalties. Licensee shall keep accurate books
and accounts of the computation of the number of Licensed Products sold and the Net Sales of Licensee, its Affiliates and Sublicensees of Licensed Products, and shall cause such Affiliates and Sublicensees to keep such records of their respective
sales of Licensed Products and Net Sales of 
  
 CONFIDENTIAL TREATMENT REQUESTED

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
Licensed Products, in sufficient detail to permit accurate determination of all figures necessary for verification of payments required to be paid hereunder,
which books and accounts shall be maintained for at least three (3) years from the end of the calendar year to which they pertain. 
 4.3.2 Review. At the request of Licensor, which shall not be made more frequently than once per calendar year during the Term, on a business day designated by Licensor upon at least thirty (30) days’ prior written notice to
Licensee, Licensee shall permit, under confidentiality obligations with terms substantially the same as those hereunder, an independent certified public accountant reasonably selected by Licensor and reasonably acceptable to Licensee to inspect
(during regular business hours) the relevant records required to be maintained by Licensee under Subsection 4.3.1. In the event such inspection reveals an underpayment, such underpayment shall be due and payable by Licensee within thirty
(30) days of the date of such inspection, together with interest thereon from the date the amount due but unpaid was first due until the date paid, at the lower of 12% per annum or the maximum rate permitted by applicable law. Such
inspection shall be at the expense of Licensor unless there is an underpayment that differs by greater than five percent (5%) from the amount that was otherwise due, in which event Licensee shall also pay the reasonable costs of the inspection.
The foregoing is without prejudice to the right of Licensee to dispute the conclusion of the accountant, but such dispute shall not relieve Licensee of its obligation to pay interest and, under the circumstances described, costs of inspection as to
amount actually due. 
 4.4 Matters Related to the Issuance of Common Stock.  
 4.4.1 Representations, Warranties and Certain Covenants of the Licensee. The Licensee represents, warrants and covenants that: 
 (a) Assuming the covenant of Licensor contained in Subsection 4.4.2 of this Agreement is complied with, the issuance to Licensor of each share of Common
Stock (all shares so issued the “Shares”) will be in compliance with all applicable federal and state securities laws in connection with the offer, issuance and sale of the securities. 
 (b) The execution, delivery and performance of this Agreement by Holdings, the issuance and sale of the Shares and the consummation by Holdings of the
other transactions by it contemplated hereby do not and will not on the date of the issuance and sale of the Shares(i) conflict with or violate any provision of Holdings’ or any of its subsidiaries certificates or articles of incorporation,
bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any lien or encumbrance upon any
of the properties or assets of Holdings or any of its subsidiaries, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or
other instrument or other understanding to which Holdings or any of its subsidiaries is a party or by which any property or asset of Holdings or any such subsidiary is bound or affected, in each case with respect to this Subsection (ii), to a

  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
degree that would have a material adverse effect on the assets or results of operations of Holdings or its subsidiaries when considered as a whole (a
“Material Adverse Effect”), or (iii) conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which Holdings or any such
subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of Holdings or any such subsidiary is bound or affected, in each case with respect to this Subsection (iii), to a degree that
would have a Material Adverse Effect. 
 (c) Prior to the issuance of the Shares, Holdings shall obtain all consents, approvals, orders,
authorizations or registrations, qualifications, designations, declarations, and make all filings or registrations with any court or other federal, state, local or other governmental authority or other person that is required in order to issue the
Shares. 
 (d) The Shares, when issued in accordance herewith, will be (i) duly authorized, (ii) duly and validly issued,
(iii) fully paid and nonassessable, and (iv) free and clear of all liens imposed by Holdings, other than restrictions on transfer provided for herein. 
 (e) At all times prior to the second anniversary of the last issuance of the Shares during which there are Shares outstanding which have not been previously (i) sold or transferred to or through a broker or
dealer or underwriter in a public distribution, or (ii) sold or transferred in a transaction exempt from the registration and prospectus delivery requirements of the Securities Act of 1933, as amended (the “Securities Act”), in the
case of either Subsection (i) or Subsection (ii) in such a manner that, upon the consummation of such sale or transfer, all transfer restrictions and restrictive legends with respect to such Shares are removed upon the consummation of such
sale or transfer, Holdings shall use its commercially reasonable efforts to: (1) comply with the requirements of Rule 144(c) under the Securities Act with respect to current public information about Holdings, and (2) furnish to the
Licensor such non-publicly available reports and documents of Holdings as Licensor may reasonably request to avail itself of Rule 144 of the Securities Act, or any similar rule or regulation of the United States Securities Exchange Commission
allowing Licensor to sell the Shares without registration. 
 4.4.2 Representations and Warranties of the Licensor. The Licensor
represents and warrants that (i) it is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D of the Securities Act; (ii) it is acquiring the Shares for investment for the Licensor’s own account and
not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, without prejudice, however, to Licensor’s right to at all times to sell or otherwise dispose of any or all of the Shares so issued in compliance
with applicable federal and state securities laws and (iii) it does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participation to such person or to any third person, with respect to any
of such Shares. 
 4.4.3 Restrictions on the Shares. Licensor understands and agrees that the Shares may not be sold, transferred, or
otherwise disposed of without registration under the Securities Act or an exemption therefrom, and that in the absence of an effective registration statement covering the Shares or any available exemption from registration under the Securities Act,
the Shares must be held indefinitely. The Licensor agrees and acknowledges that the following legend will be placed on the back of any certificate evidencing the Shares: 
  

 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 “THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED OR HYPOTHECATED UNLESS THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT COVERING SUCH SECURITIES, THE SALE IS MADE IN ACCORDANCE WITH RULE 144 UNDER THE ACT, OR THE CORPORATION
RECEIVES AN OPINION OF COUNSEL FOR THE HOLDER OF THESE SECURITIES REASONABLY SATISFACTORY TO THE CORPORATION, STATING THAT SUCH SALE, TRANSFER, ASSIGNMENT OR HYPOTHECATION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SUCH
ACT.” 
 5. TREATMENT OF CONFIDENTIAL INFORMATION 
 5.1 Confidential Obligations. Licensor and Licensee each recognize that the other
Party’s Confidential Information constitutes highly valuable and proprietary confidential information. Licensor and Licensee each agree that during the Term and for five (5) years thereafter, it will keep confidential, and will cause its
employees, consultants, Affiliates and sublicensees to keep confidential, all Confidential Information of the other Party. Neither Licensor nor Licensee nor any of their respective employees, consultants, Affiliates or sublicensees shall use
Confidential Information of the other Party for any purpose whatsoever other than exercising any rights granted to it or reserved by it hereunder. Without limiting the foregoing, each Party may disclose information to the extent such disclosure is
reasonably necessary to (a) file, prosecute or defend litigation in accordance with the provisions of this Agreement or (b) comply with applicable laws, regulations (including those of the United States Securities Exchange Commission) or
court orders; provided, however, that if a Party is required to make any such disclosure of the other Party’s Confidential Information in connection with any of the foregoing, it will give reasonable advance notice to the other Party of such
disclosure requirement and will use reasonable efforts to cooperate with such other Party in efforts to secure confidential treatment of such information required to be disclosed. Each Party agrees that any Confidential Information disclosed by a
Party under that certain Mutual Confidentiality Agreement between the Parties dated the 10th day of August 2007 shall be protected by the
obligations set forth therein through the date hereof and from and after the date hereof shall be protected by the obligations as to Confidential Information set forth herein so as to be continuously protected. 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 5.2 Limited Disclosure and Use. Licensor and Licensee each agree that any
disclosure of the other Party’s Confidential Information to any officer, employee, consultant or agent of the other Party or any of its Affiliates or Sublicensees shall be made only if and to the extent necessary to carry out its rights and
responsibilities under this Agreement, shall be limited to the maximum extent possible consistent with such rights and responsibilities and shall only be made to the extent any such persons are bound by written confidentiality obligations to
maintain the confidentiality thereof and not to use such Confidential Information except as expressly permitted by this Agreement. Licensor and Licensee each further agree not to disclose or transfer the other Party’s Confidential Information
to any Third Parties under any circumstance without the prior written approval from the other Party (such approval not to be unreasonably withheld), except as otherwise required by law, and except as otherwise expressly permitted by this Agreement.
Each Party shall take such action, and shall cause its Affiliates or Sublicensees to take such action, to preserve the confidentiality of each other’s Confidential Information as it would customarily take to preserve the confidentiality of its
own Confidential Information, using, in all such circumstances, not less than reasonable care. Each Party, upon the request of the other Party, will return all the Confidential Information disclosed or transferred to it by the other Party pursuant
to this Agreement, including all copies and extracts of documents and all manifestations in whatever form, within sixty (60) days of such request or, if earlier, the termination or expiration of this Agreement; provided however, that a Party
may retain (i) any Confidential Information of the other Party relating to any license which expressly survives such termination, and (ii) one (1) copy of all other Confidential Information in inactive archives in legal counsel’s
files solely for the purpose of establishing the contents thereof. 
 5.3 Publicity. Neither Party may publicly disclose the
existence or terms or any other matter of fact regarding this Agreement without the prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed; provided, however, that either Party may make such a
disclosure (i) to the extent required by law or by the requirements of any nationally recognized securities exchange, quotation system or over-the-counter market on which such Party has its securities listed or traded, or (ii) with respect
to Licensee, to any prospective Sublicensees, or to investors, prospective investors, lenders and other potential financing sources, who are obligated to keep such information confidential. The Parties, upon the execution of this Agreement, will
mutually agree to a press release with respect to this transaction for publication. Once such press release or any other written statement is approved for disclosure by both Parties, neither Party may make subsequent public disclosure of the
contents of such statement without the further approval of the other Party. 
 5.4 Use of Name. Neither Party shall
employ or use the name of the other Party in any promotional materials or advertising without the prior express written permission of the other Party. 
 6. PROVISIONS CONCERNING THE FILING, PROSECUTION AND MAINTENANCE OF PATENT RIGHTS 
 6.1 Certain
Patent Filing, Prosecution and Maintenance. Subject to its right of abandonment or other forfeiture, Licensor shall be responsible, at its cost, for preparing, filing and prosecuting the patent applications listed in Schedule A, and
available foreign 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
counterparts to such patent applications in [***] using patent counsel reasonably chosen by Licensor (which in any event includes [***]), and for maintaining
any patents obtained thereon. Licensor shall keep Licensee reasonably appraised as to the prosecution of each such patent application. Licensor agrees to send Licensee copies of all file histories and prosecution documents for each of the patent
applications of the Licensed Patent Rights, within thirty (30) days of receipt by Licensor. Licensor shall have the right in its discretion to abandon or otherwise cause or allow to be forfeited, any Licensed Patent Rights (each a
“Discontinued Patent”). Licensor shall give Licensee at least sixty (60) days written notice prior to abandonment or other forfeiture of any such Discontinued Patent so as to permit Licensee to exercise its rights under
Section 6.3. 
 6.2 Requests for Other Patent Filing, Prosecution and Maintenance. Licensee may reasonably request that
Licensor seek patent protection of the Licensed Patent Rights and/or Licensed Technology in addition to that contemplated by Section 6.1 by written notice to Licensor. 
 6.3 Right to Effect Other Patent Filing, Prosecution and Maintenance. Subject to any right of another licensee existing as of the Effective
Date of all or any part of the Licensed Patent Rights or Licensed Technology, as to any Discontinued Patent or as to any patent with respect to which Licensor refuses in its discretion to seek such additional patent protection in response to a
request from Licensee in accordance with Section 6.2 (a “Refused Patent”), Licensee shall have the right, but not the obligation, to file, in the name of Licensor, for protection as to such Discontinued Patent or Refused Patent.
Licensee shall bear all costs associated with the preparation, filing, prosecution and maintenance of all such Discontinued Patents and Refused Patents; provided that Licensee shall have the right to deduct from Net Sales, on a country-by-country
basis, [***] percent ([***] %) of the amount of such costs borne by Licensee with respect to each such Discontinued Patents and Refused Patents that Licensee has filed in such country in the name of Licensor. All such Discontinued Patents or Refused
Patents filed by Licensee in the name of Licensor shall be included in the Licensed Technology. Nothing in this Section 6.3 shall be deemed to limit Licensor’s right to file, prosecute or maintain patent applications at its own expense in
any country. 
 6.4 Notice of Infringement or Claims. If, during the Term, either Party learns of any (i) actual, alleged
or threatened infringement by a Third Party of any Licensed Patent Rights or Licensed Technology, (ii) attack on the enforceability or validity of any Licensed Patent Rights or Licensed Technology, or (iii) claim by a Third Party alleging
that the development or commercialization of a Licensed Product infringes or otherwise violates the intellectual property rights of such Third Party, then such Party shall promptly notify the other Party of the same and shall provide such other
Party with available details as to and evidence of such infringement, suit or claim. 
 6.5 Infringement of Patent Rights.
Licensee shall have the first right (but not the obligation), at its own expense and with legal counsel of its own choice, to bring suit (or take other appropriate legal action) against any actual, alleged or threatened infringement of the Licensed
Patent Rights or Licensed Technology in the Licensed Field. Such right includes the right to settle the infringement claim, provided that such settlement may not encompass matters 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
beyond the scope of the license grant set forth in Section 2.1 and if such settlement would include Licensee’s agreement to the invalidity or
unenforceability of any claim within the Licensed Patent Rights or Licensed Technology, Licensor must first approve in writing such settlement, which approval shall not be unreasonably withheld. Any damages, monetary awards or other amounts
recovered, whether by judgment or settlement, pursuant to any suit, proceeding or other legal action taken by Licensee under this Section 6.5, shall applied as follows: 
 (a) first, to reimburse the cost of Licensee for its reasonable costs and expenses (including reasonable attorneys’ fees and costs) incurred in
prosecuting such enforcement action; 
 (b) second, to reimburse the costs of Licensor for its reasonable costs and expenses (including
reasonable attorneys’ fees and costs) incurred in such enforcement action; 
 (c) third, to Licensee in reimbursement for lost sales
associated with Licensed Products and to Licensor in reimbursement for lost royalties, it being agreed that for such purpose such lost sales shall equate to Net Sales; and 
 (d) fourth, any amounts remaining shall be allocated to each Party on a pro rata basis based on each Party’s losses attributable to the
infringement. 
 If Licensee brings any such action or proceeding hereunder, Licensor agrees to be joined as party plaintiff if necessary to prosecute such
action or proceeding, and to give Licensee reasonable assistance and authority to file and prosecute the suit. Licensee shall bear Licensor’s costs, including costs of responding to discovery, arising from involvement in such action or
proceeding as and when incurred, subject to clause (a) of this Section 6.5; provided that in the event Licensor elects to actively participate in such action by counsel of Licensor’s own choice, the incremental expense thereof shall
be Licensor’s, subject to clause (b) of this Section 6.5. In no event shall Licensor being a party to or represented in any such action by Licensee affect the right of Licensee to control the suit as described in the first sentence of
this Section 6.5. If Licensee fails to take any action it is permitted to take by this Section 6.5 to obtain a discontinuance of such infringement or to bring suit against the infringer within four (4) months of having knowledge of
such infringement, Licensor shall have the right but not the obligation to enforce the Licensed Patents Rights at its expense and for its sole benefit. For the avoidance of doubt, neither Licensee’s nor Licensor’s failure to enforce the
Licensed Patent Rights in any way affects the rights granted to or responsibilities of Licensee under the Agreement. 
 6.6 Information
and Updating. Each Party controlling any action to enforce the Licensed Patent Rights shall use commercially reasonable efforts to inform and update the other Party with respect to all material aspects of actual or potential enforcement
actions, providing copies of all material documents in connection with any enforcement action and notice of any and all material developments, including, without limitation, any other challenges (threatened or pending) affecting the Licensed Patent
Rights; provided that Licensor shall have no such obligation as to any enforcement action outside the Licensed Field. 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 7. REPRESENTATIONS AND WARRANTIES 
 7.1 Representations and Warranties of Licensor. As of the Effective Date, Licensor represents and warrants to Licensee as follows:

 7.1.1 it owns and controls the Licensed Patents Rights and Licensed Technology and has the right to grant the exclusive licenses within
the Licensed Field free and clear of all encumbrances, and no Third Party has notified Licensor that the Third Party is claiming any ownership of or right to the Licensed Patents Rights or Licensed Technology; 
 7.1.2 it has not received any notice of invalidity or infringement of any of the Licensed Patent Rights or Licensed Technology; and 
 7.1.3 it is not a party to any agreements which would be inconsistent with the licenses granted herein or the exercise of the license granted under this
Agreement. 
 7.2 Representations and Warranties of each Party and Holdings. As of the Effective Date, each Party and
Holdings represents and warrants as follows: 
 7.2.1 the execution, delivery and performance of this Agreement will not constitute a
violation, be in conflict with, or result in a breach of any agreement or contract to which it is bound; 
 7.2.2 it is a corporation or
entity duly organized and validly existing under the laws of the state or other jurisdiction of incorporation or formation; 
 7.2.3 the
execution, delivery and performance of this Agreement by it has been duly authorized by all requisite corporate action and do not require any shareholder action or approval; 
 7.2.4 it has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder; and 
 7.2.5 it shall at all times comply with all applicable material laws and regulations relating to its activities under the Agreement 
 7.3 No Warranties. Nothing in this Agreement is or shall be construed as a warranty or representation that anything made, used, sold or
otherwise disposed of under any license granted pursuant to this Agreement is or will be free from infringement of patents, copyrights, and other rights of Third Parties. EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE 7, EACH PARTY EXCLUDES ALL OTHER
REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING AMONG SUCH EXCLUDED REPRESENTATIONS AND WARRANTIES ANY AND ALL REPRESENTATIONS OR WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 8. INDEMNIFICATION 
 8.1 Indemnification. 
 8.1.1
Licensee Indemnity. Licensee shall indemnify, defend and hold harmless Licensor, its Affiliates and their respective directors, officers, employees, stockholders and agents and their respective successors, heirs and assigns (the
“Licensor Indemnitees”) from and against any claims, liability, damage, loss or expense (including reasonable attorneys’ fees and expenses of litigation) incurred by or imposed upon such Licensor Indemnitee, or any of them, in
connection with any Third Party claims, suits, actions, demands or judgments to the extent arising out of or related to (i) the design, development, testing, production, manufacture, supply, promotion, marketing, importation, sale, use or
instructions for use of any Licensed Product (or any component thereof) manufactured or sold by Licensee or any Affiliate or Sublicensee under this Agreement, including without limitation any claims that (a) the design of any Licensed Product
by Licensee infringed the intellectual property right of any Third Party or (b) any Licensed Product manufactured or sold by Licensee or any Affiliate or Sublicensee under this Agreement caused the death of any person or any injury to any
person or property, (ii) any material breach of any representation or warranty by Licensee in Article 7 of this Agreement. 
 8.1.2
Licensor Indemnity. Licensor shall indemnify, defend and hold harmless Licensee, its Affiliates and their respective directors, officers, employees, stockholders and agents and their respective successors, heirs and assigns (the
“Licensee Indemnitees”) from and against any claims, liability, damage, loss or expense (including reasonable attorneys’ fees and expenses of litigation) incurred by or imposed upon such Licensee Indemnitee, or any of them, in
connection with any Third Party claims, suits, actions, demands or judgments to the extent arising out of any material breach of any representation or warranty by Licensor in Article 7 of this Agreement. 
 8.2 Indemnification Procedures. In the event that any Indemnitee is seeking indemnification under Section 8.1 above from a Party (the
“Indemnifying Party”), the Indemnitee shall notify the Indemnifying Party of such claim with respect to such Indemnitee as soon as reasonably practicable after the Indemnitee receives notice of the claim, and the Party seeking
indemnification, on behalf of itself and such Indemnitee, shall permit the Indemnifying Party to assume direction and control of the defense of the claim (including the right to settle the claim solely for monetary consideration) and shall cooperate
as requested (at the expense of the Indemnifying Party) in the defense of the claim. The indemnification obligations under Article 8 shall not apply to any harm suffered as a direct result of any delay in notice to the Indemnifying Party hereunder
or to amounts paid in settlement of any claim, demand, action or other proceeding if such settlement is effected without the consent of the Indemnifying Party, which consent shall not be withheld or delayed unreasonably. The Indemnitee, its
employees and agents, shall reasonably cooperate with the Indemnifying Party and its legal representatives in the investigation of any claim, demand, action or other proceeding covered by Section 8.1. 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 9. TERM AND TERMINATION 
 9.1 Expiration. The term of this Agreement shall commence on the Effective Date and expire twenty (20) years after the First Commercial
Sale (the “Term”). Following the Term, Licensee shall have a fully paid-up, irrevocable, freely transferable and sublicensable license in the Territory under the Licensed Patent Rights and Licensed Technology, to develop, have developed,
make, have made, use, have used, sell, have sold, offer for sale, import and have imported any and all Licensed Products in the Licensed Field. 
 9.2 Termination Rights for Breach and Voluntary Termination. 
 9.2.1 Termination for Breach. Subject to the
other terms of this Agreement, this Agreement and the rights granted herein may be terminated by either Party upon any material breach by the other Party of any material obligation or condition, effective ninety (90) days after giving written
notice to the breaching Party of such termination, which notice shall describe such breach in reasonable detail. The foregoing notwithstanding, if such material breach is cured or remedied or shown to be non-existent or not to be material within the
aforesaid ninety (90) day period, the notice shall be automatically withdrawn and of no effect. 
 9.2.2 Voluntary Termination.
Licensee shall have the right to terminate this Agreement effective as of the first day of any calendar year upon not less than ninety (90) days prior written notice to Licensor. 
 9.3 Effects of Termination. 
 9.3.1 Certain Effects of Termination. Upon any termination of this Agreement: (i) as of the effective date of such termination all relevant licenses and sublicenses granted by Licensor to Licensee hereunder, and any sublicense
granted by Licensee to any Sublicensee, shall terminate automatically, (ii) all payment or other rights or obligations accrued hereunder prior to termination shall survive the expiration or termination of the Term; (iii) except in respect
of a termination by Licensor under Subsection 9.2.1, Licensee and its Affiliates and Sublicensees shall have the right, for [***] ([***]) months or such longer time period as upon which the Parties mutually agree in writing, to sell or
otherwise dispose of all finished Licensed Products then on hand, with royalties to be paid to Licensor on all Net Sales of such Licensed Products as provided for in this Agreement, and (iv) by Licensor under Subsection 9.2.1 or by Licensee
under Subsection 9.2.2, Licensee shall not, nor shall it permit its Affiliates to, for a period of [***] following such termination in the event such termination is effective prior to the First Commercial Sale and for a period of [***] following
such termination in the event such termination is effective on or after the First Commercial Sale, engage in any business anywhere in the Territory, whether as a sole proprietor, partner, shareholder, consultant, agent, independent contractor,
trustee or otherwise, to hold any beneficial interest in any business, incorporated or otherwise, which designs, develops, tests, produces, manufactures, supplies, promotes, markets, imports or sells any product in the Licensed Field, or any
component thereof (a “Competing Business”), derive any income from any interest in a Competing Business, or provide any service or assistance to a Competing Business; provided that the foregoing will not restrict Licensee from owning a
passive interest of less than five percent (5.0%) of the outstanding stock of a corporation engaged in a Competing Business. 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 9.4 Remedies. Except as otherwise expressly set forth in this Agreement, the
termination provisions of this Article 9 are in addition to any other relief and remedies available to either Party at law. 
 9.5
Surviving Provisions. Notwithstanding any provision herein to the contrary, the rights and obligations of the Parties set forth in Subsections 3.1.1 (with respect to Licensee’s ownership of Technology), Sections 3.3, 3.4, 4.3,
7.3, 9.3, 9.4, 9.5 and Articles 5, 8, 10, and 11 (to the extent relevant) shall survive the expiration or termination of this Agreement. 
 10. DISPUTES 
 10.1 Negotiation. The Parties recognize that a bona fide dispute as to certain matters may from
time to time arise during the term of this Agreement that relates to either Party’s rights and/or obligations hereunder. In the event of the occurrence of such a dispute, either Party may, by written notice to the other Party, have such dispute
referred to their respective senior officials designated below or their successors, for attempted resolution by good faith negotiations within sixty (60) days after such notice is received. Said designated senior officials are as follows:

 For Licensee: President and Chief Executive Officer 
 For Licensor: Chief Executive Officer 
 In the event the designated senior officials are not able to resolve such dispute
within the sixty (60) day period, either Party may invoke the provisions of Section 10.2. 
 10.2 Arbitration.
Subject to Section 10.1, any dispute, controversy or claim initiated by either Party arising out of, resulting from or relating to this Agreement, or the performance by either Party of its obligations under this Agreement (other than bona fide
Third Party actions or proceedings filed or instituted in an action or proceeding by a Third Party against a Party), whether before or after termination of this Agreement, shall be finally resolved by binding arbitration. Whenever a Party shall
decide to institute arbitration proceedings, it shall give written notice to that effect to the other Party. Any such arbitration shall be conducted under the Commercial Arbitration Rules of the American Arbitration Association by one arbitrator
appointed in accordance with such rules. Any such arbitration shall be held in New York, New York. The method and manner of discovery in any such arbitration proceeding shall be governed by the laws of the State of New York. The arbitrator
shall have the authority to grant injunctions and/or specific performance and to allocate between the parties the costs of arbitration in such equitable manner as they determine. Judgment upon the award so rendered may be entered in any court having
jurisdiction or application may be made to such court for judicial acceptance of any award and an order of enforcement, as the case may be. In no event shall a demand for arbitration be made after the date when institution of a legal or equitable
proceeding based upon such claim, dispute or other matter in question would be barred by the 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
applicable statute of limitations. Notwithstanding the foregoing, either Party shall have the right, without waiving any right or remedy available to such
Party under this Agreement or otherwise, to seek and obtain from any court of competent jurisdiction any interim or provisional relief that is necessary or desirable to protect the rights or property of such Party, pending the selection of the
arbitrators hereunder or pending the arbitrators’ determination of any dispute, controversy or claim hereunder. 
 11. MISCELLANEOUS

 11.1 Notification. All notices, requests and other communications hereunder shall be in writing, shall be addressed to
the receiving Party’s address set forth below or to such other address as a Party may designate by notice hereunder, and shall be either (i) delivered by hand, (ii) sent by nationally-recognized overnight courier service providing
evidence of receipt, or (iii) sent by registered or certified mail, return receipt requested, postage prepaid. The addresses and other contact information for the parties are as follows: 
  

			
	If to Licensor:	  	 Progressive Spinal Technologies LP
 410 East Walnut
Street, Suite #8
 Perkasie, Pennsylvania 18944
 Attn: Chief
Executive Officer

		
	With a copy to:	  	 Oppenheimer Wolff & Donnelly
 Plaza VII Building,
Suite 3300
 45 South Seventh Street
 Minneapolis, Minnesota 55402

 (612) 607-7397
 Attn: Dennis P. Whelpley

		
	If to Licensee:	  	 Alphatec Spine, Inc.
 2051 Palomar Airport Road, Suite
100
 Carlsbad, CA 92011
 (760) 431-9286 (ext. 169)
 Attn: President and CEO

		
	With a copy to:	  	 Heller Ehrman LLP
 Times Square Tower
 7 Times Square
 New York, New York 10036
 Attention: Blaine Templeman
 Telephone: (212) 847-8572
 Fax: (212) 763-7600
 Email:
blaine.templeman@hellerehrman.com

  
 CONFIDENTIAL TREATMENT REQUESTED

 CONFIDENTIAL TREATMENT REQUESTED 
  

 All notices, requests and other communications
hereunder shall be deemed to have been given either (i) if by hand, at the time of the delivery thereof to the receiving Party at the address of such Party set forth above, (ii) if made by telecopy or facsimile transmission, at the time
that receipt thereof has been acknowledged by the recipient, (iii) if sent by nationally-recognized overnight courier, on the day such notice is delivered to the recipient, or (iv) if sent by registered or certified mail, on the fifth (5
th) business day following the day such mailing is made. 
 11.2 Governing Law. This Agreement will be construed and interpreted in accordance with the laws of the State of New York. 
 11.3 Limitations. Except as expressly set forth in this Agreement, neither Party grants to the other Party any right or license to any of its intellectual property. 
 11.4 Entire Agreement. This is the entire Agreement between the Parties with respect to the subject matter hereof and supersedes all prior
representations, understandings and agreements between the Parties with respect to the subject matter hereof. No modification shall be effective unless in writing with specific reference to this Agreement and signed by the Parties. No modification
shall be effective unless in writing with specific reference to this Agreement and signed by the Parties. 
 11.5 Waiver. The
terms or conditions of this Agreement may be waived only by a written instrument executed by the Party waiving compliance. The failure of either Party at any time or times to require performance of any provision hereof shall in no manner affect its
rights at a later time to enforce the same. No waiver by either Party of any condition or term shall be deemed as a continuing waiver of such condition or term or of another condition or term. 
 11.6 Headings. Section, Subsection and Paragraph headings are inserted for convenience of reference only and do not form part of this
Agreement. 
 11.7 Assignment. Neither this Agreement nor any right or obligation hereunder may be assigned, delegated or
otherwise transferred, in whole or part, by either Party without the prior express written consent of the other Party; provided that a Party may freely assign this Agreement, including all rights and obligations hereunder, at any time to any entity
acquiring in the same transaction substantially all of such Party’s business and assets, including those to which this Agreement relates, whether by way of sale, merger, consolidation or other transaction without the prior written consent of
the other Party. Any permitted assignee shall assume all obligations of its assignor under this Agreement. Any purported assignment in violation of this Section 11.7 shall be void. The terms and conditions of this Agreement shall be binding
upon and inure to the benefit of the permitted successors and assigns of the parties. 
 11.8 Force Majeure. Neither Party
shall be liable for failure of or delay in performing obligations set forth in this Agreement, and neither shall be deemed in breach of its obligations, for so long as and to the extent that such failure or delay is due to natural disasters or any
causes beyond the reasonable control of such Party. In event of such force majeure, the Party affected thereby shall use reasonable efforts to cure or overcome the same and resume performance of its obligations hereunder. 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 11.9 Construction. The Parties hereto acknowledge and agree that: (i) each Party
and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision; (ii) the rule of construction to the effect that any ambiguities are resolved against the drafting Party shall not be
employed in the interpretation of this Agreement; and (iii) the terms and provisions of this Agreement shall be construed fairly as to all Parties hereto and not in favor of or against any Party, regardless of which Party was generally
responsible for the preparation of this Agreement. 
 11.10 Severability. If any provision(s) of this Agreement are or become
invalid, are ruled illegal by any court of competent jurisdiction or are deemed unenforceable under then current applicable law from time to time in effect during the Term hereof, it is the intention of the Parties that the remainder of this
Agreement shall not be affected thereby provided that a Party’s rights under this Agreement are not thereby materially diminished. The Parties hereto covenant and agree to renegotiate any such term, covenant or application thereof in good faith
in order to provide a reasonably acceptable alternative to the term, covenant or condition of this Agreement or the application thereof that is invalid, illegal or unenforceable, it being the intent of the Parties that the basic purposes of this
Agreement are to be effectuated. 
 11.11 Status. Nothing in this Agreement is intended or shall be deemed to constitute a
partner, agency, employer-employee, or joint venture relationship between the Parties. 
 11.12 Section 365(n). All
licenses granted under this Agreement are deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of right to “intellectual property” as defined in Section 101 of such Code. The Parties agree that
Licensee may fully exercise all of its rights and elections under the U.S. Bankruptcy Code, regardless of whether either Party files for bankruptcy in the United States or other jurisdiction. 
 11.13 Further Assurances. Each Party agrees to execute, acknowledge and deliver such further instructions, and to do all such other acts,
as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
 11.14 Counterparts. This
Agreement may be executed simultaneously in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 11.15 Guarantee and Agreement of Alphatec Holding, Inc. By its signature below, Holdings hereby guarantees the full
and timely payment and performance of all obligations of Licensee under this Agreement and agrees to issue shares to Licensor consistent with the terms of this Agreement, including without limitation Section 4.4 hereof. 
 [remainder of page intentionally left blank] 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 IN WITNESS WHEREOF, the Parties and Holdings have caused this Agreement to be executed by their duly
authorized representative. 
  

									
	ALPHATEC SPINE, INC.	 		 		 	PROGRESSIVE SPINAL TECHNOLOGIES LLC:
					
	By:	 	 /s/ Dirk Kuyper
	 		 	By:	 	 /s/ E. Skott Greenhalgh

	Name:	 	Dirk Kuyper	 		 	Name:	 	E. Skott Greenhalgh
	Title:	 	President and CEO	 		 	Title:	 	CEO

  

			
	ALPHATEC HOLDINGS, INC.
		
	By:	 	 /s/ Dirk Kuyper

	Name:	 	Dirk Kuyper
	Title:	 	President and CEO

  
 CONFIDENTIAL TREATMENT REQUESTED

 Schedule A 
 Licensed Patent Rights 
  

											
	 Docket #
	  	 Invention Name
	  	 Application No.
	  	 Filing Date
	  	 Application Type
	  	 Inventors

 [***] 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 Schedule B 
 Licensor Assistance and Compensation 
 LICENSED PRODUCT Responsibilities 
  

			
	 Task
	  	 Responsibility

	 [***]
	  	[***]

 [***] 
  
 CONFIDENTIAL TREATMENT REQUESTED

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}]]